Skip to main content
OpenTrials
Completed

NCT Number: NCT02717078

The LoBAG Diet and Type 2 Diabetes Mellitus

The proposed study is a randomized controlled, pilot effectiveness trial comparing the LoBAG diet to a control diet in 38 participants with DM2 over 12 weeks. Participants will have DM2 that is not under ideal glycemic control (HgbA1c 7.0-9.5%) and must be taking no glycemic medications or metformin. Participants will be free-living (given diet instruction and dietitian support, but asked to prepare meals in their own homes). The primary endpoint will be HgbA1c, measured at baseline and at the end of the 12-week diet intervention. Additional outcome measures will include: weight, fasting plasma glucose, fasting serum insulin, postprandial plasma glucose and serum insulin following a test meal consistent with the assigned diet, serum fructosamine, fasting serum lipids, stool samples for gut microbiome analysis, and surveys to assess quality of life, including the Diabetes Treatment Satisfaction Questionnaire. Compliance outcomes will include: urine nitrogen to creatinine ratio, survey data, three-day food diaries, and unannounced 24-hour diet recalls.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Minnesota

Minneapolis, Minnesota, 55455, United States

About this study

Thirty-eight adult men and women with DM2 will be recruited from the University of Minnesota and surrounding communities, and will be randomized to treatment with the LoBAG diet or a control diet. Following a consent and screening visit, there will be 5 additional study visits over a 12-week diet intervention period. Instruction in the assigned diet will be provided by a research dietitian at the beginning of the 12-week period, and reinforced at subsequent visits throughout the study. Participants will be asked to purchase food, prepare food, and consume the assigned diet in their own homes. They will be asked to keep activity level constant and to continue medications for diabetes (metformin or no medication) without change during the intervention. The primary outcome, HgbA1c, and secondary outcome measures will be assessed at baseline and following diet intervention. Study visits will occur at baseline (visits 1 and 2), week 1 (visit 3), week 6 (visit 4), week 9 (visit 5) and week 12 (final study visit). In addition to scheduled study visits the research team will contact participants every other week by telephone to address any issues that arise, with the purpose of increasing compliance and retention. Participants will be contacted once in weeks 9-12 for a 24-hour diet recall collected by the Nutrition Coordinating Center at the University of Minnesota. Study procedures will conclude after the 12-week diet intervention period and collection of all outcome measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Diagnosis of type 2 diabetes mellitus
  • Hemoglobin A1c of 7.0-9.5%
  • Taking no medications for diabetes or taking metformin

Exclusion criteria

  • Type 1 diabetes mellitus
  • Treatment with insulin
  • BMI < 27 kg/m^2
  • Change in weight of more than 5 pounds in the prior 3 months
  • Estimated glomerular filtration rate (GFR) < 60 ml/minute/1.73 m^2
  • Urine albumin > 300 mg/g creatinine
  • Anemia
  • Pregnancy or immediate plans to become pregnant
  • Current breast feeding
  • Use of antibiotics in the 3 month period prior to study enrollment
  • Dietary restriction(s) that would preclude consumption of the study diets
  • Inability or unwillingness to prepare meals
  • Presence of any disease which would make adherence to the study protocol difficult

Treatment and study plan

Diet therapy

Other

The intervention for both study groups will be a change in diet.

Primary outcomes

  1. Change in Hemoglobin A1c From Baseline to Week 12

    Time frame: Week 12

    Marker of blood sugar control

Secondary outcomes

  1. Change in Weight From Baseline to Week 12

    Time frame: Week 12

    Weight in pounds

  2. Change in Fasting Plasma Glucose From Baseline to Week 12

    Time frame: Week 12

    Blood draw

  3. Change in Fasting Serum Insulin From Baseline to Week 12

    Time frame: Week 12

    Blood draw

  4. Postprandial Plasma Glucose and Serum Insulin Following a Test Meal

    Time frame: Baseline

    A meal will be provided, and blood drawn at regular intervals for 4 hours following the meal

  5. Postprandial Plasma Glucose and Serum Insulin Following a Test Meal

    Time frame: Week 12

    A meal will be provided, and blood drawn at regular intervals for 4 hours following the meal

  6. Change in Serum Fructosamine From Baseline to Week 12

    Time frame: Week 12

    A marker of blood sugar control, similar to hemoglobin A1c

  7. Change in Fasting Serum Lipids From Baseline to Week 12

    Time frame: Week 12

    Blood draw

  8. Diabetes Treatment Satisfaction Questionnaire Score

    Time frame: Week 12

    Questionnaire to determine satisfaction with current diabetes treatment, scored 0 (very dissatisfied) to 36 (very satisfied)

  9. Gut Microbiome Composition

    Time frame: Baseline

    The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

  10. Gut Microbiome Composition

    Time frame: Week 6

    The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

  11. Gut Microbiome Composition

    Time frame: Week 12

    The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

  12. Urine Nitrogen to Creatinine Ratio

    Time frame: Baseline

    Urine sample

  13. Urine Nitrogen to Creatinine Ratio

    Time frame: Week 3

    Urine sample

  14. Urine Nitrogen to Creatinine Ratio

    Time frame: Week 6

    Urine sample

  15. Urine Nitrogen to Creatinine Ratio

    Time frame: Week 9

    Urine sample

  16. Urine Nitrogen to Creatinine Ratio

    Time frame: Week 12

    Urine sample

  17. Three-day Food Diary

    Time frame: Baseline

    Meal record for 3 days

  18. Three-day Food Diary

    Time frame: Week 6

    Meal record for 3 days

  19. Three-day Food Diary

    Time frame: Week 12

    Meal record for 3 days

  20. 24-hour Diet Recall

    Time frame: Week 9

    Interview to review meals consumed in previous 24 hours

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

A Weight Neutral, High Protein, Moderate Carbohydrate Diet for Treatment of Type 2 Diabetes Mellitus

Important dates

Study start
2017
Primary completion
2023
Study completion
2023
First posted
Mar 23, 2016
Registry last updated
Jul 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.